|
1-1 (of 1) related articles
Items per page
| |
|
1. Merrill Lynch: Teva will beat estimates: Merrill Lynch is the latest...
Byline: Gil Shlomo Jul. 19--Merrill Lynch has retained its "Neutral" recommendation for Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) in its latest review, although ... (PREMIUM PERIODICAL ARTICLE) | |
|
1-1 (of 1) related articles
Items per page
1-1 (of 1) related articles
|